The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Adrian MinsonDuring the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Adrian Minson, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, Can we combine targeted therapy with chimeric antigen receptor (CAR) T-cell therapies in mantle cell lymphoma (MCL)?
TARMAC: Can we combine targeted therapy with CAR T-cells in MCL?
Minson explains why there is a drive to develop new therapies that will lead to more durable remissions in patients with MCL, and how immunotherapeutic agents, such as CAR T-cell therapies, have been beneficial but not without their challenges. Minson then reviews the positive impact of combining ibrutinib with CAR T-cell therapy and examines data on response, survival, and toxicity from the TARMAC trial (NCT04234061), in which this combination was used as a treatment option for MCL.